Compare Bristol-Myers Squibb Co (BMY) vs Riot Platforms Inc (RIOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Riot Platforms Inc — how do they compare? Bristol-Myers Squibb Co trades at $57.81 (market cap $116.30B), while Riot Platforms Inc trades at $20.42 (market cap $7.64B). The key difference: Bristol-Myers Squibb Co is far larger — about 15.2× Riot Platforms Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Riot Platforms Inc pays none. Which is the better fit depends on your goals.
| BMY | RIOT | |
|---|---|---|
Market Cap | $116.30B | $7.64B |
Sector | Health | Technology |
52-Week High | $62.37 | $28.67 |
52-Week Low | $42.60 | $11.03 |
Enterprise Value | $152.24B | $8.31B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
RIOT stock trades at $20.19, down 3.7% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $663.18 million in 2025, with a negative net income margin of -132.76%, though revenue reached $647.44 million. Analyst consensus remains strongly bullish with a $27.86 price target, supported by 17 buy ratings. Recent news highlights volatility amid broader crypto stock trends and a strategic pivot toward high-performance computing.
The outlook is mixed: strong analyst support and a strategic shift to data centers offer upside, but persistent losses, negative cash flow from operations, and sensitivity to Bitcoin market swings pose significant risks. Investors should weigh the high valuation multiples against the company's unprofitability and execution challenges in its expansion plans.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Riot Platforms Inc
Riot Platforms, Inc. is a Bitcoin mining company that focuses on building, operating, and expanding large-scale infrastructure for digital asset mining in North America. The company's operations include Bitcoin mining, data center hosting, and engineering solutions. Riot's strategy emphasizes vertical integration to maximize efficiency and scale its mining capacity, aiming to be a leader in the global Bitcoin and digital infrastructure industry.
Read more on RIOT →
